Bicocca Open Archive

Logo unimib boa
SQUILLACE, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.768
AS - Asia 3.360
EU - Europa 2.874
SA - Sud America 651
Continente sconosciuto - Info sul continente non disponibili 366
AF - Africa 98
OC - Oceania 7
Totale 14.124
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.431
SG - Singapore 1.186
IT - Italia 828
CN - Cina 612
HK - Hong Kong 479
BR - Brasile 474
VN - Vietnam 453
RU - Federazione Russa 443
DE - Germania 423
SE - Svezia 307
CA - Canada 262
IE - Irlanda 256
GB - Regno Unito 149
ID - Indonesia 126
IN - India 107
BD - Bangladesh 96
FR - Francia 93
UA - Ucraina 74
AR - Argentina 70
FI - Finlandia 59
IQ - Iraq 45
NL - Olanda 43
DK - Danimarca 42
MX - Messico 40
PL - Polonia 36
KR - Corea 35
ZA - Sudafrica 35
TR - Turchia 34
AT - Austria 31
JP - Giappone 30
PK - Pakistan 27
EC - Ecuador 26
CO - Colombia 21
PH - Filippine 17
BE - Belgio 16
SA - Arabia Saudita 15
UZ - Uzbekistan 15
CL - Cile 14
ES - Italia 14
VE - Venezuela 14
PY - Paraguay 13
CH - Svizzera 12
CR - Costa Rica 12
MA - Marocco 12
KE - Kenya 11
PE - Perù 11
MY - Malesia 10
LT - Lituania 8
EG - Egitto 7
TH - Thailandia 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
BG - Bulgaria 6
KZ - Kazakistan 6
DZ - Algeria 5
ET - Etiopia 5
JM - Giamaica 5
JO - Giordania 5
OM - Oman 5
SN - Senegal 5
AU - Australia 4
CZ - Repubblica Ceca 4
IL - Israele 4
IR - Iran 4
LB - Libano 4
MD - Moldavia 4
NG - Nigeria 4
NP - Nepal 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
BY - Bielorussia 3
EU - Europa 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
RS - Serbia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GR - Grecia 2
HN - Honduras 2
KH - Cambogia 2
LU - Lussemburgo 2
LY - Libia 2
MM - Myanmar 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
SR - Suriname 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
Totale 13.747
Salva come PNG Salva come JPEG
Città #
Ann Arbor 926
Singapore 720
Ashburn 579
Hong Kong 470
San Jose 435
Frankfurt am Main 303
New York 285
Fairfield 281
Dublin 246
Chandler 240
Milan 213
Wilmington 198
Toronto 181
Houston 146
Santa Clara 144
Woodbridge 142
Los Angeles 134
Ho Chi Minh City 131
Council Bluffs 130
Seattle 109
Chicago 108
Jakarta 105
Beijing 94
Princeton 91
Dallas 89
Hanoi 89
The Dalles 77
Cambridge 75
Hefei 68
Rome 65
Dearborn 56
Jacksonville 54
Lauterbourg 49
São Paulo 47
Dong Ket 41
Lawrence 41
Shanghai 41
Phoenix 39
Altamura 38
Moscow 37
Buffalo 36
London 35
Seoul 33
Helsinki 32
San Diego 31
Guangzhou 30
Nanjing 29
Nuremberg 29
Boardman 28
Tokyo 28
Brooklyn 26
Atlanta 25
Ottawa 25
Columbus 24
Johannesburg 24
Rio de Janeiro 23
Warsaw 22
Amsterdam 19
Figino 19
Da Nang 18
Denver 18
Fremont 18
Vienna 18
Boston 17
Montreal 17
Naples 17
Bologna 16
Orem 15
Andover 14
Baghdad 14
Brussels 14
Chennai 14
Munich 14
Tashkent 14
Falls Church 13
Poplar 13
Biên Hòa 12
Guayaquil 12
Monza 12
Changsha 11
Dhaka 11
Hải Dương 11
Lappeenranta 11
Pune 11
Salt Lake City 11
Stockholm 11
Tampa 11
Turin 11
Curitiba 10
Palermo 10
Philadelphia 10
San José 10
Washington 10
Belo Horizonte 9
Bogotá 9
Can Tho 9
Edmonton 9
Lachine 9
Manchester 9
Nairobi 9
Totale 8.347
Salva come PNG Salva come JPEG
Nome #
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 612
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 383
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 373
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 361
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 354
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 337
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 333
Brachial and central blood pressure in HIV-infected subjects 330
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 325
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 312
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 305
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare 304
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 298
A multidisciplinary approach to screen the post-COVID-19 conditions 287
Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti? 275
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 271
Arterial structure and function in AIDS patients: the impact of renal damage. 268
Weight gain: A possible side effect of all antiretrovirals 264
Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment? 263
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 261
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 259
Unmasking tuberculosis in the era of antiretroviral treatment 257
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 248
Ruolo delle strutture ambulatoriali extra-ospedaliere per pazienti con COVID-19: l’esperienza dell’Hotspot COVID di Monza. Role of outpatient facilities for patients with COVID-19: the experience of the COVID Hotspot in Monza. 246
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 245
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 231
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 226
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study 225
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 223
Factors Associated With Weight Gain in People Treated With Dolutegravir 223
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 222
Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients. 221
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 220
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 203
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 200
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 200
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 199
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 198
Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible from the STOPSHIV Project Cohort 194
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 192
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 186
Factors associated with hospital admission for COVID-19 in HIV patients 186
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort 185
Incident diabetes in course of antiretroviral therapy 182
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study 179
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 175
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients 175
Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study 172
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens 171
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 170
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? 168
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? 167
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile 164
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 160
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda 155
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir 149
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project 147
Reversibility of Central Nervous System Adverse Events in Course of Art 143
HIV and SARS-CoV-2 Co-Infection: What are the Risks? 142
Totale 14.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.045
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.045
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022472 0 0 0 61 19 48 18 34 18 60 68 146
2022/20231.272 135 346 108 104 67 193 23 103 84 21 50 38
2023/20241.037 51 18 69 29 119 315 165 48 83 27 7 106
2024/20252.021 92 219 107 116 175 135 109 57 193 341 174 303
2025/20265.548 576 451 373 581 571 257 701 229 409 400 338 662
2026/20271.057 203 190 504 160 0 0 0 0 0 0 0 0
Totale 14.124